Enrollment for the HEALEY ALS Platform Trial Starts at Several Sites

Over the past few months, the Healey Center faculty and staff have worked tirelessly to adapt the HEALEY ALS Platform Trial to the COVID-19 pandemic and prepare for launch. Several locations are now enrolling their initial patients, with more to follow.

Read the full announcement

The HEALEY ALS Platform Trial is a collaborative effort, and enrollment in the trial is available at several sites across the US to bring the trial close to people who want to participate. If you have site-specific questions, please click here to contact the site where you would like to participate. For general inquiries, please contact healeyalsplatform@mgh.harvard.edu.

This groundbreaking approach cuts the time to find an effective treatment in half, decreases costs by a third or more, and is supported by our patients, the FDA, ALS clinicians and scientists and our pharma colleagues.

 Saves TimeSaves Money Merit Cudkowicz, MD, MSc
Director, Sean M. Healey & AMG Center for ALS

We fully anticipate that more treatments will be added to the HEALEY ALS Platform Trial, supported by pharma, foundation partners, philanthropy, federal and other fundraising initiatives. We encourage the academic and industry community to engage with the Healey Center ALS Trial Design Team at any time to work together on ALS therapy development. Nominations of therapies for inclusion in the platform trial will continue on an ongoing, rolling basis.

Platform Trial Presentation

Platform Trial Presentation

View slides from the 30th International Symposium on ALS/MND in Perth, Australia.

Thanks to Our Supporters

Thanks to Our Supporters

The HEALEY ALS Platform Trial is supported by many foundations and generous donors.